Researchers in the U.K. are looking for healthy volunteers who are willing to be infected with the novel coronavirus in a bid to speed up vaccination development. The approach, called a human challenge trial (HCT), is not unheard of, as similar trials take place in the U.S. each year involving the influenza virus. In fact, U.S.-based non-profit 1Day Sooner has already had over 38,000 people sign up for a potential coronavirus human challenge trial.
However, the U.K. trial is being conducted in conjunction with the government, which according to a press release posted Tuesday is prepared to put over $43 million into the study. Imperial College London, the Department for Business, Energy and Industrial Strategy, the Royal Free London NHS Foundation Trust and hVivo are all prepared to play a role in the study.
The researchers are looking for up to 90 healthy volunteers between the ages of 18 and 30, and hope to determine the smallest level of exposure to coronavirus needed to cause the disease. According to a press release, the volunteers will be compensated for the time they spend in the study and followed for up to one year after it ends to ensure long-term well-being.
The second phase will follow the same model to study how potential coronavirus vaccines work in the body, the body’s immune response to the illness and potential treatments.
If the trial is approved by regulators and an ethics committee, the work could begin as early as January with results expected by May.
“We are doing everything we can to fight coronavirus, including backing our best and brightest scientists and researchers in their hunt for a safe and effective vaccine,” Business Secretary Alok Sharma said in the press release. “The funding announced today for these ground-breaking but carefully controlled studies marks an important step in building on our understanding of the virus and accelerating the development of our most promising vaccines which will ultimately help in beginning our return to normal life.”
Dr. Chris Chiu, of the department of infectious disease at Imperial College London, will lead the study and said his team has been safely conducting such trials involving respiratory viruses for the last 10 years.
“No study is completely risk-free, but the Human Challenge Programme partners will be working hard to ensure we make the risks as low as we possibly can,” he said. “The U.K.’s experience and expertise in human challenge trials as well as in wider coronavirus science will help us tackle the pandemic, benefiting people in the U.K. and worldwide.”
As of Tuesday, the Johns Hopkins University coronavirus map reported more than 744,120 confirmed cases in the U.K., and nearly 44,000 deaths.